Merck-0.17%
Merck, Ridgeback to supply 3 million courses of molnupiravir
Merck and Ridgeback Biotherapeutics will sign a "long-term supply agreement" with the United Nations Children’s Fund (UNICEF) to ensure global access to molnupiravir, the COVID-19 oral drug.
According to a press note released by Merck, they will allocate a total of 3 million courses of molnupiravir "for distribution in more than 100 low- and middle-income countries following regulatory authorizations".
"Merck is delivering on our commitment to make molnupiravir available – widely, quickly, and equitably. Through this groundbreaking agreement with UNICEF, millions of patients in more than 100 low- and middle-income countries will gain access to molnupiravir through UNICEF and the ACT Accelerator Therapeutics Partnership in the first half of 2022," stated Robert M. Davis, chief executive officer and president.